Prescreening to Increase Therapeutic Oncology Trial Enrollment at the Largest Public Hospital in the United States

Jennifer Wu, Amin Yakubov, Maher Abdul-Hay, Erica Love, Gianna Kroening, Deirdre Cohen, Christy Spalink, Ankeeta Joshi, Arjun Balar, Kathie Ann Joseph, Joseph Ravenell, Janice Mehnert

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

PURPOSE:The recruitment of underserved patients into therapeutic oncology trials is imperative. The National Institutes of Health mandates the inclusion of minorities in clinical research, although their participation remains under-represented. Institutions have used data mining to match patients to clinical trials. In a public health care system, such expensive tools are unavailable.METHODS:The NYU Clinical Trials Office implemented a quality improvement program at Bellevue Hospital Cancer Center to increase therapeutic trial enrollment. Patients are screened through the electronic medical record, tumor board conferences, and the cancer registry. Our analysis evaluated two variables: number of patients identified and those enrolled into clinical trials.RESULTS:Two years before the program, there were 31 patients enrolled. For a period of 24 months (July 2017 to July 2019), we identified 255 patients, of whom 143 (56.1%) were enrolled. Of those enrolled, 121 (84.6%) received treatment, and 22 (15%) were screen failures. Fifty-five (38.5%) were referred to NYU Perlmutter Cancer Center for therapy. Of the total enrollees, 64% were female, 56% were non-White, and overall median age was 55 years (range: 33-88 years). Our participants spoke 16 different languages, and 57% were non-English-speaking. We enrolled patients into eight different disease categories, with 38% recruited to breast cancer trials. Eighty-three percent of our patients reside in low-income areas, with 62% in both low-income and Health Professional Shortage Areas.CONCLUSION:Prescreening at Bellevue has led to a 4.6-fold increase in patient enrollment to clinical trials. Future research into using prescreening programs at public institutions may improve access to clinical trials for underserved populations.

Original languageEnglish
Pages (from-to)E620-E625
JournalJCO Oncology Practice
Volume18
Issue number4
DOIs
StatePublished - 1 Apr 2022
Externally publishedYes

Fingerprint

Dive into the research topics of 'Prescreening to Increase Therapeutic Oncology Trial Enrollment at the Largest Public Hospital in the United States'. Together they form a unique fingerprint.

Cite this